Stanley Laman Group Ltd. Takes Position in Corcept Therapeutics Incorporated $CORT

Stanley Laman Group Ltd. purchased a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the 3rd quarter, HoldingsChannel reports. The fund purchased 24,483 shares of the biotechnology company’s stock, valued at approximately $2,035,000.

Several other large investors also recently added to or reduced their stakes in CORT. Golden State Wealth Management LLC purchased a new position in Corcept Therapeutics during the second quarter worth about $28,000. Huntington National Bank boosted its position in shares of Corcept Therapeutics by 54.0% during the 2nd quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 168 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in shares of Corcept Therapeutics during the third quarter worth about $56,000. Employees Retirement System of Texas purchased a new position in shares of Corcept Therapeutics during the second quarter worth about $52,000. Finally, USA Financial Formulas bought a new position in shares of Corcept Therapeutics in the second quarter worth approximately $56,000. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Price Performance

Shares of Corcept Therapeutics stock opened at $38.20 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14. Corcept Therapeutics Incorporated has a 52-week low of $32.99 and a 52-week high of $117.33. The company has a fifty day moving average of $76.45 and a 200-day moving average of $74.83. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of 43.41 and a beta of 0.23.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). The business had revenue of $207.64 million during the quarter, compared to analysts’ expectations of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.Corcept Therapeutics’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.41 EPS. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Insider Buying and Selling

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $89.94, for a total value of $1,798,800.00. Following the transaction, the insider directly owned 5,287 shares of the company’s stock, valued at $475,512.78. The trade was a 79.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $73.99, for a total value of $1,479,800.00. Following the completion of the sale, the insider owned 7,904 shares of the company’s stock, valued at $584,816.96. The trade was a 71.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 196,700 shares of company stock worth $15,474,198 in the last ninety days. Corporate insiders own 20.50% of the company’s stock.

Key Stores Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord cut its price target from $140 to $99 but kept a “buy” rating, signaling some sell‑side conviction that there is still meaningful upside from current levels if the company resolves regulatory issues or demonstrates efficacy in follow‑up data. Benzinga
• Neutral Sentiment: Options implied volatility has surged, reflecting elevated uncertainty and trader interest; that can amplify price moves (both rebounds and further declines) and is likely contributing to today’s bounce as short squeezes / gamma flows unwind. Implied Volatility Surging for Corcept Stock Options
• Neutral Sentiment: Unusually large options trading was reported around CORT, consistent with the volatility spike; that activity can produce sharp intraday rallies even when fundamentals remain unchanged. Monitor open interest and large‑block trades for clues to whether the move is technical/speculative versus a change in fundamentals. Corcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)
• Negative Sentiment: The FDA issued a Complete Response Letter for relacorilant, saying the agency needs additional evidence of effectiveness for treating hypercortisolism (Cushing’s). That CRL drove the prior ~50%+ collapse in the share price and is the core fundamental headwind — approval now requires more data or discussions with the FDA that could delay or derail the drug’s U.S. launch. Corcept Receives Complete Response Letter for Relacorilant
• Negative Sentiment: Multiple outlets summarize the practical impact: analysts and investors marked down valuations and the stock hit new lows after the FDA decision — this is an ongoing risk to revenue/cash‑flow forecasts if relacorilant was a key growth driver. Corcept Tanks on FDA’s CRL to Relacorilant NDA in Hypercortisolism
• Negative Sentiment: Kaplan Fox has alerted investors to a possible securities‑law investigation into Corcept, which can prolong downside pressure and raise potential legal/settlement expenses. This increases headline risk even if operational issues are later resolved. Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a research report on Wednesday. Wall Street Zen cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price for the company. in a research report on Wednesday, December 31st. UBS Group started coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $80.83.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.